In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells

Carcinogenesis

Volumn 17, Issue 12, 1996, Pages 2763-2769

  Saris, C P ^a   Van de Vaart, P J M ^a   Rietbroek, R C ^b   Blommaert, F A ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOSTATIC AGENT; DNA; LOBAPLATIN; OXALIPLATIN;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CELL CULTURE; CELL KILLING; CELL NUCLEUS; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DNA CROSS LINKING; DRUG DNA INTERACTION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; THYMUS;

ANTINEOPLASTIC AGENTS; CISPLATIN; CYCLOBUTANES; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KINETICS; ORGANOPLATINUM COMPOUNDS; SOLUTIONS; TUMOR CELLS, CULTURED;

EID: 0030464203     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/17.12.2763     Document Type: Article

References (28)

1. Christian,M.C. (1992) The current status of new platinum analogs [review]. Semin. Oncol., 19, 720-733.
2. Voegeli,R., Schumacher,W., Engel,J., Respondek,J. and Hilgard,P. (1990) D-19466, a new cyclobutane-platinum complex with antitumour activity. J. Cancer Res. Clin. Oncol., 116, 439-442.
3. Harstrick,A., Bokemeyer,C., Scharnofkse,M., Hapke,G., Reile,D. and Schmoll,H.J. (1993) Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines. Cancer Chemother. Pharmacol., 33, 43-47.
4. Gietema,J.A., Guchelaar,H.J., de Vries,E.G., Aulenbacher,P., Sleijfer,D.T. and Mulder,N.H. (1993) A phase I study of lobaplatin (D-19466) administered by 72 h continuous infusion. Anticancer Drugs, 4, 51-55.
5. Gietema,J.A., de Vries,E.G., Sleijfer,D.T., Willemse,P.H., Guchelaar,H.J., Uges,D.R., Aulenbacher,P., Voegeli,R. and Mulder,N.H. (1993) A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. Br. J. Cancer, 67, 396-401.
6. Chaney,S.G. (1995) The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand [review]. Int. J. of Oncol., 6, 1291-1305.
7. Burchenal,J.H., Kalaher,K., O'Toole,T. and Chisholm,J. (1977) Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia. Cancer Res., 37, 3455-3457.
8. Schmidt,W. and Chaney,S.G. (1993) Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res., 53, 799-805.
9. Los, G., Mutsaers, P.H., Ruevekamp, M. and McVie,J.G. (1990) The use of oxaliplatin versus cisplatin in intraperitoneal chemotherapy in cancers restricted to the peritoneal cavity in the rat. Cancer Lett., 51, 109-117.
10. Levi,F., Perpoint,B., Garufi,C., Focan,C., Chollet,P., Depres-Brummer,P., Zidani,R., Brienza,S., Itzhaki,M., Iacobelli,S. et al. (1993) Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur. J. Cancer, 29A, 1280-1284.
11. Levi,F.A., Zidani,R., Vannetzel,J.M., Perpoint,B., Focan,C., Faggiuolo,R., Chollet,P., Garufi,C., Itzhaki,M., Dogliotti,L. et al. (1994) Chrono-modulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J. Natl Cancer Inst., 86, 1608-1617.
12. Poirier,M.C., Reed,E., Zwelling,L.A., Ozols,R.F., Litterst,C.L. and Yuspa,S.H. (1985) Polyclonal antibodies to quantitate cis-diamminedichloroplatinum(II)-DNA adducts in cancer patients and animal models. Environ. Health Perspect, 62, 89-94.
13. Fichtinger-Schepman,A.M., Baan,R.A., Luiten-Schuite,A., van Dijk,M. and Lohman,P.H. (1985) Immunochemical quantitation of adducts induced in DNA by cis-diamminedichloroplatinum (II) and analysis of adduct-related DNA-unwinding. Chem.-Biol. Interactions, 55, 275-288.
14. Terheggen,P.M., Floot,B.G., Lempers,E.L., van Tellingen,O., Begg,A.C. and den Engelse,L. (1991) Antibodies against against cisplatin modified DNA and cisplatin modified dinucleotides. Cancer Chemother. Pharmacol., 8(3), 185-191.
15. Yamada,H., Kato,T., Hirose,J., Inagaki,K., Noji,M. and Kidani,Y. (1990) Antibodies against (1R,2R)-cyclohexanediamineplatinum(II)-DNA adduct recognize the conformational differences of isomeric analogues of cyclohexanediamine. Biochim. Biophys. Acta, 1049, 298-302.
16. Jennerwein,M.M, Eastman,A. and Khokhar,A. (1989) Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes. Chem.-Biol. Interactions, 70, 39-49.
17. 32P-postlabelling. Nucleic Acids Res., 23, 1300-1306.
18. Fichtinger-Schepman,A.M.J., van Oosterom,A.T., Lohman,P.H.M. and Berends,F. (1987) cis-Diaminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diaminedichloroplatinum(II). Cancer Res., 47, 3000-3004.
19. Terheggen, P.M.A.B., Floot,B.G. J., Scherer,E., Begg,A.C., Fichtinger-Schepman,A.M.J. and den Engelse,L. (1987) Immunocytochemical detection of interaction products of cis-diamine-dichloro-Pt(II) and cis-diamine(1,1-cyclobutanedicarboxylato)Pt(II) with DNA in rodent tissue sections. Cancer Res., 47, 6719-6725.
20. Blommaert,F.A., Michael,C., Terheggen,P.M., Muggia,F.M., Kortes,V., Schornagel,J.H., Hart,A.A. and den Engelse,L. (1993) Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response. Cancer Res., 53, 5669-5675.
21. Fichtinger-Schepman,A.M.J., van Dijk-Knijnenburg,H.C. Dijt,F.J., van der Velde-Visser,S.D., Berends,F. and Baan,R. (1994) Effects of thiourea and ammonium bicarbonate on the formation and stability of bifunctional cisplatin-DNA adducts; consequences for the accurate quantification of adducts in (cellular) DNA. J. Inorg. Biochem., 58, 177-195.
22. Gibbons,G.R., Page,J.D. and Chaney,S.G. (1991) Treatment of DNA with ammonium bicarbonate or thiourea can lead to underestimation of platinum-DNA monoadducts. Cancer Chemother. Pharmacol., 29, 112-116.
23. Eastman,A. (1986) Reevaluation of interaction of cis-dichloro-(ethylenediamine)platinum(II) with DNA. Biochemistry, 25, 3912-3915.
24. Knox,R.J., Friedlos,F., Lydall,D.A. and Roberts,J.J. 11986) Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diaminedichloroplatinum(II) and cis-diamine-(1,1-cyclo-butanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res., 46, 1972-1979.
25. Blommaert,F.A., van Dijk-Knijnenburg,H.C.M., Dijt,F.J., den Engelse,L., Baan,R., Berends,F. and Fichtinger-Schepman,A.M.J. (1995) Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry, 34, 8474-8480.
26. 2-(CDBCA-O)(5′-GMP-N7)) in solution. Inorg. Chem., 32, 1333-1340.
27. Cleare,M.J., Hydes,P.C., Malerbi,B.W. and Watkins,D.M. (1978) Antitumour platinum complexes: relationships between chemical properties and activity. Biochimie, 60, 835-850.
28. Tonetti,M., Giovine,M., Gasparini,A., Benatti,U. and DeFlora,A. (1993) Enhanced formation of reactive species from carboplatin in the presence of oxygen free radicals. Biochem. Pharmacol., 46, 1377-1383.